{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:30Z","timestamp":1793042130676,"version":"4.5.0"},"reference-count":82,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment landscape for cancer therapy has changed drastically over the past decade. Tisagenlecleucel, the first genetically engineered adoptive cellular therapy approved by the United States Food and Drug Administration, has revolutionized this field by demonstrating impressive clinical success in children and young adults with relapsed\/refractory B\u2010cell acute lymphoblastic leukemia (r\/r B\u2010ALL). Now 3\u00a0years since its approval, we have gained a deeper understanding on the basic immunobiology and clinical efficacy of this drug. This review will provide an updated summary of tisagenlecleucel in childhood and young adults with r\/r B\u2010ALL, common side effects and their associated management strategies, as well as barriers that remain to be addressed in order to realize the maximum potential of this drug.<\/jats:p>","DOI":"10.1002\/pbc.29123","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T02:14:18Z","timestamp":1622600058000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Tisagenlecleucel for treatment of children and young adults with relapsed\/refractory B\u2010cell acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-581X","authenticated-orcid":false,"given":"Stephanie J.","family":"Si Lim","sequence":"first","affiliation":[{"name":"Department of Pediatrics University of Pennsylvania Perelman School of Medicine  Philadelphia Pennsylvania USA"},{"name":"Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"},{"name":"Division of Pediatric Oncology\u2010Hematology, University of Hawai'i Cancer Center Kapi'olani Medical Center for Women and Children  Honolulu Hawaii USA"},{"name":"Department of Pediatrics University of Hawai'i School of Medicine  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Pennsylvania Perelman School of Medicine  Philadelphia Pennsylvania USA"},{"name":"Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"DiNofia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Pennsylvania Perelman School of Medicine  Philadelphia Pennsylvania USA"},{"name":"Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.251"},{"key":"e_1_2_7_3_1","unstructured":"FDA.FDA Approves Tisagenlecleucel for B\u2010cell ALL and Tocilizumab for Cytokine Release Syndrome.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed September 26 2020."},{"key":"e_1_2_7_4_1","unstructured":"Novartis.Kymriah (Tisagenlecleucel) the First\u2010in\u2010Class CAR\u2010T Therapy from Novartis Receives Second FDA Approval to Treat Appropriate r\/r Patients with Large B\u2010Cell Lymphoma.https:\/\/www.novartis.com\/news\/media-releases\/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma. Accessed July 18 2020."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21219"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70580-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23169"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","unstructured":"BrownPAM JiLP XuXM et\u00a0al.A randomized phase 3 trial of blinatumomab vs. chemotherapy as post\u2010reinduction therapy in high and intermediate risk (HR\/IR) first relapse of B\u2010acute lymphoblastic leukemia (B\u2010ALL) in children and adolescents\/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331. Paper presented at: Blood 2019.","DOI":"10.1182\/blood-2019-132435"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.176"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00342-x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128977"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112599"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_2_7_26_1","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR\u2010T\u2010cell\u2010induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si S","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.008"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"e_1_2_7_31_1","unstructured":"Novartis.Cytokine Release Syndrome Treatment Algorithm.2018.https:\/\/www.hcp.novartis.com\/products\/kymriah\/acute-lymphoblastic-leukemia-children\/safety-profile\/"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1084"},{"key":"e_1_2_7_38_1","volume-title":"Chimeric Antigen Receptor (CAR)\u2010modified T cells (CTL019) Induce Durable Remissions in Children with CNS\/Combined Bone Marrow and CNS Relapsed\/Refractory CD19+ Acute Lymphoblastic Leukemia","author":"Talekar M","year":"2017"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477"},{"key":"e_1_2_7_41_1","volume-title":"Janeway's Immunology","author":"Murphy K","year":"2017"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28092"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2997"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_2_7_46_1","unstructured":"FDA.Kymriah: Highlights of Prescribing Information.2017. 1234.https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138765"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5222"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1314"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39748"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000169"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782888"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0960-135X.2004.01366.x"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27265"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018093"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0265-z"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3007"},{"key":"e_1_2_7_77_1","doi-asserted-by":"crossref","unstructured":"LiA HucksG SeifAE et\u00a0al.American Society of Hematology; December 1\u20134 2018 San Diego CA.https:\/\/ashpublications.org\/blood\/article\/132\/Supplement%201\/556\/263334\/Checkpoint-Inhibitors-Augment-CD19-Directed","DOI":"10.1182\/blood-2018-99-112572"},{"issue":"1","key":"e_1_2_7_78_1","first-page":"1319","article-title":"Durable remissions with humanized CD19\u2010targeted chimeric antigen receptor (CAR)\u2010modified T cells in CAR\u2010naive and CAR\u2010exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"130","author":"Maude S","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.586.586"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.105"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127346"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:22:46Z","timestamp":1692685366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/pbc.29123"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29123","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29123"}}